AG
MCRB icon

Artal Group’s Seres Therapeutics MCRB Stock Holding History

Artal Group’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,000
Closed -$4.77M – 155
2021
Q2 		$4.77M Hold
10,000
– – 0.1% 121
2021
Q1 		$4.12M Hold
10,000
– – 0.07% 125
2020
Q4 		$4.9M Sell
10,000
-5,000
-33% -$2.93M 0.11% 110
2020
Q3 		$8.49M Buy
+15,000
New +$4.99M 0.21% 81
2018
Q1 		– Sell
-15,000
Closed -$3.04M – 126
2017
Q4 		$3.04M Sell
15,000
-12,500
-45% -$2.57M 0.05% 85
2017
Q3 		$8.82M Sell
27,500
-2,500
-8% -$683K 0.15% 50
2017
Q2 		$6.78M Hold
30,000
– – 0.12% 51
2017
Q1 		$6.76M Sell
30,000
-5,000
-14% -$1.01M 0.15% 50
2016
Q4 		$6.93M Buy
35,000
+10,000
+40% +$2.18M 0.15% 47
2016
Q3 		$6.14M Buy
25,000
+9,500
+61% +$3.33M 0.12% 49
2016
Q2 		$9.01M Buy
15,500
+4,250
+38% +$2.49M 0.19% 34
2016
Q1 		$5.98M Buy
11,250
+2,500
+29% +$1.3M 0.12% 39
2015
Q4 		$6.14M Sell
8,750
-1,250
-13% -$822K 0.12% 61
2015
Q3 		$5.93M Buy
10,000
+1,997
+25% +$1.63M 0.13% 53
2015
Q2 		$6.64M Buy
+8,003
New +$6.98M 0.29% 52

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Artal Group's MCRB Position: Q3 2021 in Review

Artal Group sold out of Seres Therapeutics (MCRB) in Q3 2021, closing a stake of 10,000 shares — an estimated $4.77M sold.

Artal Group first reported a position in MCRB in Q2 2015 and held it in 15 quarters. The position peaked at $9.01M in Q2 2016. 133 funds tracked by Wall St. Rank hold MCRB as of Q3 2021.

  • Artal Group reported no remaining Seres Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Artal Group sold 10,000 Seres Therapeutics shares in Q3 2021, an estimated $4.77M.
  • Artal Group first reported a position in Seres Therapeutics in Q2 2015 and held it in 15 quarters.
  • Artal Group's Seres Therapeutics position peaked at $9.01M in Q2 2016.
  • 133 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2021.

Based on Artal Group's 13F filing for Q3 2021, filed 12 Nov 2021.